(IMVT) Immunovant - Ratings and Ratios
Antibody, Graves, Arthritis, Myasthenia, Neuropathy
IMVT EPS (Earnings per Share)
IMVT Revenue
Description: IMVT Immunovant
Immunovant, Inc. is a clinical-stage immunology company that focuses on developing monoclonal antibodies to treat various autoimmune diseases, including Graves disease, rheumatoid arthritis, and myasthenia gravis. The companys pipeline includes IMVT-1402 and batoclimab, both of which have shown potential in treating these conditions.
From a business perspective, Immunovant has a license agreement with HanAll Biopharma Co., Ltd. for the intellectual property rights related to its lead products. As a subsidiary of Roivant Sciences Ltd., Immunovant leverages its parent companys resources and expertise to drive its research and development efforts. Key performance indicators (KPIs) to watch include the companys cash runway, R&D expenses as a percentage of revenue, and the progress of its clinical trials.
In terms of financials, Immunovants market capitalization stands at approximately $3.06 billion. Given its stage of development, the company does not have a price-to-earnings (P/E) ratio. Return on Equity (ROE) is negative, at -80.60%, indicating significant investment in research and development. Other relevant KPIs include the companys burn rate, the number of patients enrolled in its clinical trials, and the expected timeline for regulatory approvals.
To evaluate Immunovants potential, its essential to monitor the progress of its clinical trials, particularly the efficacy and safety data for IMVT-1402 and batoclimab. Additionally, investors should keep an eye on the competitive landscape, including the development of similar treatments by other biotechnology companies. Key metrics to track include the companys enterprise value, the number of shares shorted, and the overall sentiment among analysts and investors.
IMVT Stock Overview
| Market Cap in USD | 2,627m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2019-06-21 |
IMVT Stock Ratings
| Growth Rating | 5.13% |
| Fundamental | 21.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -56.2% |
| Analyst Rating | 4.64 of 5 |
IMVT Dividends
Currently no dividends paidIMVT Growth Ratios
| Growth Correlation 3m | -36.9% |
| Growth Correlation 12m | -84.6% |
| Growth Correlation 5y | 26.4% |
| CAGR 5y | 46.35% |
| CAGR/Max DD 3y | 0.66 |
| CAGR/Mean DD 3y | 1.68 |
| Sharpe Ratio 12m | -1.51 |
| Alpha | 0.22 |
| Beta | 0.428 |
| Volatility | 57.31% |
| Current Volume | 2056.2k |
| Average Volume 20d | 1412.2k |
| Stop Loss | 14.4 (-5.8%) |
| Signal | -0.25 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-447.3m TTM) > 0 and > 6% of Revenue (6% = 9600 TTM) |
| FCFTA -0.57 (>2.0%) and ΔFCFTA -20.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 374.3k% (prev 36.3k%; Δ 338.0kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.63 (>3.0%) and CFO -417.1m > Net Income -447.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 12.32 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (170.9m) change vs 12m ago 16.97% (target <= -2.0% for YES) |
| Gross Margin -134.4% (prev 63.27%; Δ -197.6pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.03% (prev 0.25%; Δ -0.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -32.44
| (A) 0.91 = (Total Current Assets 651.8m - Total Current Liabilities 52.9m) / Total Assets 661.4m |
| (B) -2.06 = Retained Earnings (Balance) -1.36b / Total Assets 661.4m |
| warn (B) unusual magnitude: -2.06 — check mapping/units |
| (C) -0.70 = EBIT TTM -438.4m / Avg Total Assets 625.6m |
| (D) -25.68 = Book Value of Equity -1.36b / Total Liabilities 52.9m |
| Total Rating: -32.44 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 21.84
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -18.10% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.09 = 2.50 |
| 5. Debt/Ebitda -0.12 = -2.50 |
| 6. ROIC - WACC (= -90.36)% = -12.50 |
| 7. RoE -84.49% = -2.50 |
| 8. Rev. Trend 9.64% = 0.72 |
| 9. EPS Trend -77.61% = -3.88 |
What is the price of IMVT shares?
Over the past week, the price has changed by -6.77%, over one month by +0.20%, over three months by -1.29% and over the past year by -48.05%.
Is Immunovant a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IMVT is around 14.06 USD . This means that IMVT is currently overvalued and has a potential downside of -8.04%.
Is IMVT a buy, sell or hold?
- Strong Buy: 10
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the IMVT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 39.5 | 158.1% |
| Analysts Target Price | 39.5 | 158.1% |
| ValueRay Target Price | 15.5 | 1.6% |
Last update: 2025-09-04 04:40
IMVT Fundamental Data Overview
CCE Cash And Equivalents = 598.9m USD (Cash And Short Term Investments, last quarter)
P/B = 4.208
Beta = 0.661
Revenue TTM = 160.0k USD
EBIT TTM = -438.4m USD
EBITDA TTM = -438.0m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 52.9m USD (from totalCurrentLiabilities, last quarter)
Debt = 52.9m USD (Calculated: Short Term 52.9m + Long Term 0.0)
Net Debt = -598.9m USD (from netDebt column, last quarter)
Enterprise Value = 2.08b USD (2.63b + Debt 52.9m - CCE 598.9m)
Interest Coverage Ratio = unknown (Ebit TTM -438.4m / Interest Expense TTM 0.0)
FCF Yield = -18.10% (FCF TTM -376.6m / Enterprise Value 2.08b)
FCF Margin = -235.4k% (FCF TTM -376.6m / Revenue TTM 160.0k)
Net Margin = -279.6k% (Net Income TTM -447.3m / Revenue TTM 160.0k)
Gross Margin = -134.4% ((Revenue TTM 160.0k - Cost of Revenue TTM 375.0k) / Revenue TTM)
Tobins Q-Ratio = -1.53 (set to none) (Enterprise Value 2.08b / Book Value Of Equity -1.36b)
Interest Expense / Debt = 7.68% (Interest Expense 4.07m / Debt 52.9m)
Taxrate = 21.0% (US default)
NOPAT = -438.4m (EBIT -438.4m, no tax applied on loss)
Current Ratio = 12.32 (Total Current Assets 651.8m / Total Current Liabilities 52.9m)
Debt / Equity = 0.09 (Debt 52.9m / last Quarter total Stockholder Equity 608.5m)
Debt / EBITDA = -0.12 (Net Debt -598.9m / EBITDA -438.0m)
Debt / FCF = -0.14 (Debt 52.9m / FCF TTM -376.6m)
Total Stockholder Equity = 529.4m (last 4 quarters mean)
RoA = -67.63% (Net Income -447.3m, Total Assets 661.4m )
RoE = -84.49% (Net Income TTM -447.3m / Total Stockholder Equity 529.4m)
RoCE = -82.80% (Ebit -438.4m / (Equity 529.4m + L.T.Debt 0.0))
RoIC = -82.80% (NOPAT -438.4m / Invested Capital 529.4m)
WACC = 7.56% (E(2.63b)/V(2.68b) * Re(7.59%)) + (D(52.9m)/V(2.68b) * Rd(7.68%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 3.54%
Discount Rate = 7.59% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -376.6m)
EPS Correlation: -77.61 | EPS CAGR: -38.87% | SUE: -0.12 | # QB: 0
Revenue Correlation: 9.64 | Revenue CAGR: 0.0% | SUE: N/A | # QB: None
Additional Sources for IMVT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle